Skip to main content

Psoriatic Arthritis Content

NPF Endorsed Features
Lauren Mateja, Managing Editor
It is hypothesized that psoriatic arthritis is too often underdiagnosed, and therefore undertreated, in dermatology. In an interview with The Dermatologist, Drs Joseph F. Merola and Alice B. Gottlieb shared their insights as dual dermatologist-rheumatologists on screening for psoriatic arthritis in the patient with psoriasis.
Conferences, Videos
At the 2020 Winter Clinical Dermatology Conference, Dr Merola and Dr Gottlieb spoke about their innovative sleeve for diagnosis psoriatic arthritis in the dermatology clinic.
NPF Endorsed Features
Melissa Weiss, Associate Editor
Access restrictions to therapies among patients with rheumatoid arthritis and psoriatic arthritis can significantly impact treatment effectiveness and adherence. Natalie Boytsov, PhD, discussed the implications of these restrictions with The Dermatologist.
News
In a recent study, researchers investigated the association between gluten consumption and risk for developing psoriasis, psoriatic arthritis, and atopic dermatitis.
News
Fatigue is a common and debilitating symptom among patients with psoriatic arthritis. In a recent study, researchers identified multiple clinical and disease-related factors that contribute to fatigue in this patient population.
News
A recent systematic review compared the safety and efficacy of several biologics and disease-modifying antirheumatic drugs (DMARDS) for the treatment of active psoriatic arthritis among patients who were biologic-naïve or experienced.
News
In a recent study, researchers examined whether higher body mass index affected response to abatacept among patients with psoriatic arthritis.
News
Findings from a recent study presented at the EULAR 2019 highlighted the risk for certain cancers among patients with psoriatic arthritis treated with tumor necrosis factor inhibitors.
News
A recent study showed increases in serum lipid levels among patients with psoriatic arthritis treated with a Janus kinase inhibitor; however, cardiovascular adverse events were low.
News
Findings from a recent study showed long term treatment of psoriasis with an oral molecule was associated with maintenance of clinical benefit and no new safety signals.
Back to Top